

LCMV gp33-41 TFA

Cat. No.: HY-P1569A
Molecular Formula: C₅₀H₇₄N₁₁F₃₀₁₅S
Molecular Weight: 1158.24
Sequence: Lys-Ala-Val-Tyr-Asn-Phe-Ala-Thr-Met
Sequence Shortening: KAVYNFATM
Target: Arenavirus
Pathway: Anti-infection
Storage: Sealed storage, away from moisture
 Powder -80°C 2 years
 -20°C 1 year

KAVYNFATM (TFA salt)

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (86.34 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
	Concentration				
	1 mM		0.8634 mL	4.3169 mL	8.6338 mL
	5 mM		0.1727 mL	0.8634 mL	1.7268 mL
	10 mM		0.0863 mL	0.4317 mL	0.8634 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (2.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.16 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.16 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes^[1].

REFERENCES

[1]. Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA